previous arrow
next arrow
Slider

Please find below the latest news from Yourgene Health, formerly Premaitha Health. We also share this news across social media networks.

  • 18 February 2019 - Yourgene Health Announces Capital and Commercial Restructuring with Major Shareholder +

    Yourgene Health plc

    (“Yourgene” or the “Company”)

    Yourgene Health Announces Capital and Commercial Restructuring

    with Major Shareholder

    Manchester, UK – 18 February 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces a restructuring of its financial and commercial relationship with Life Technologies Limited (“Life Technologies”).

    Lyn Rees, CEO of Yourgene Health, commented:

    “I am delighted with the restructuring of our relationship with Life Technologies, which places Yourgene

    Read More
  • 8 January 2019 - High throughput NIPT solution for clinical laboratories +

    Yourgene Health plc
    (“Yourgene”, the “Company”)
     
    Yourgene launches Sage™ 32 plex
     
    High throughput NIPT solution for clinical laboratories
     
    Manchester, UK – 8 January 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, is pleased to announce the launch of the Sage™ 32 plex test, a new high throughput non-invasive prenatal testing (“NIPT”) and analysis solution for clinical laboratories. 
     
    Sage™ 32 plex uses the latest
    Read More
  • 3 December 2018 - Half-year Results +

    yourgene health logo RGB

    Yourgene Health plc
    (“Yourgene”, the “Company” or the “Group”)

    Half-year Results

    Manchester, UK – 3 December 2018: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year results for the six months ended 30 September 2018.

    Financial highlights

    •    Revenues increased by 45% to £3.9m (H1 2017-18: £2.7m)
    •    Gross profit up 49% to £2.0m (H1 2017-18: £1.3m)
    •    General administrative expenses down 4% to

    Read More
  • 7 November 2018 - Change of Name to Yourgene Health plc & Change of Website Address +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Change of Name to Yourgene Health plc
    &
    Change of Website Address

    Manchester, UK – 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc (“Yourgene Health”).

    Further to the special resolution approved at the Group’s Annual General Meeting on 25 October 2018,

    Read More
  • 12 October 2018 - Trading Update & Notice of Results +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Trading Update & Notice of Results

    Manchester, UK – 12 October 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to provide an update on trading for the six-month period ended 30 September 2018 (“H1”).

    H1 revenues were approximately £3.9 million, an increase of 45 per cent over the corresponding period last year. The Company has made a strong start to the second

    Read More
  • 04 October 2018 - $1 million collaboration agreement +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    $1 million collaboration agreement
    Partnership to provide genetic testing based on next generation sequencing for oncology

    Manchester, UK – 4 October 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces a new partnership agreement between the Group’s Yourgene Bioscience division (“Yourgene”) and a leading clinical research organisation in Taiwan (the “Partner”), to deliver next generation sequencing (“NGS”) testing in oncology.

    Under the terms of

    Read More
  • 28 September 2018 - Full year results to 31 March 2018 and half-year trading update +

    Premaitha Health PLC
    (“Premaitha,” the “Company” or the “Group”)

    Full year results to 31 March 2018 and half-year trading update

    Manchester, UK – 28 September 2018: Premaitha (AIM: NIPT), a leading international molecular diagnostics group, announces its full year results for the twelve months ended 31 March 2018; and provides an update on trading in the current financial year to date.  

    Financial highlights

    Revenues increased by 100% to £6.15m (2017: £3.08m), including the first

    Read More
  • 28 September 2018 - Proposed fundraise to raise approximately £2.5 million +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDIX AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

    Read More
  • 20 September 2018 - Senior Commercial Appointment and Anticipated Directorate Change +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Senior Commercial Appointment and Anticipated Directorate Change

    Manchester, UK – 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Hayden Jeffreys to a senior commercial role within the Group and that he will be appointed to the Board as Group Commercial Director upon completion of the customary directorate appointment due diligence.

    Hayden has over 20

    Read More
  • 9 March 2016 - Premaitha signs distribution agreement with GeNext in Russia +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Wednesday, 9 March 2016

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha signs distribution agreement with GeNext in Russia

    Manchester, UK – 9 March 2016: Premaitha Health plc (AIM: NIPT), the company enabling wide scale adoption of a safe, fast, accurate and complete CE Marked non-invasive prenatal screening system, has signed an exclusive distribution agreement with GeNext LLC (‘GeNext’), to market Premaitha’s flagship IONA ® test

    Read More
  • 12 October 2015 - Independent performance study of the IONA® test published +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Monday, 12 October 2015

    Independent performance study of the IONA ® test published

    Further verification of the test showing 100% of trisomies detected and 0% false positives from 242 maternal blood samples

    Manchester, UK – 12 October 2015 – Premaitha Health plc (“Premaitha” or “the Company”, AIM: NIPT), developer of the IONA ® test, the first CE-marked non-invasive prenatal screening test (NIPT), announces the results of

    Read More
  • 13 October 2015 - In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Tuesday, 13 October 2015

    RNS 7.00am Tuesday 13th October 2015

    In-house Antenatal reflex DNA screening for Down’s syndrome, trisomy 18 and trisomy 13: a world first

    The Wolfson Institute of Preventive Medicine with the assistance of Premaitha Health plc (AIM: NIPT), is launching an in-house antenatal reflex DNA screening service on 19 October 2015. The DNA screening test estimates the risk of having a pregnancy with

    Read More
  • 14 October 2015 - Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Wednesday, 14 October

    Premaitha opens dedicated clinical laboratory with expanded capacity to meet demand for IONA® test service

    Manchester, UK – 14 October 2015 – Premaitha Health plc (AIM: NIPT, “Premaitha” or “the Company”), developer of the IONA ® test, the first CE-marked non-invasive prenatal screening test (NIPT) has expanded its in-house NIPT screening service by opening a dedicated laboratory which triples clinical capacity in response

    Read More
  • 12 November 2015 - Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Thursday, 12 November 2015

    Independent, multi-centre clinical study of the IONA® test in high risk pregnancies shows 100% detection of trisomies and 0% false positives

    Study verifies performance of the test and suitability for wider implementation of non-invasive prenatal testing

    Manchester, UK – 12 November 2015 – Premaitha Health PLC (AIM: NIPT, “Premaitha” or the “Company”), developer of the IONA® test, the first CE-marked non-invasive prenatal

    Read More
  • 2 December 2015 - Premaitha establishes the first IONA® testing service in France at LaboSud +

    Issued on behalf of Premaitha Health plc
    Manchester, UK: Wednesday, 2 December 2015


    Premaitha establishes the first IONA ® testing service in France at LaboSud

    Manchester, UK and Montpellier, France – 2 December 2015 – Premaitha Health plc (AIM: NIPT, “Premaitha” or “the Company”) developer of the IONA ® test, an advanced cell-free DNA prenatal screening test, has appointed Adgenix as its exclusive distributor in France. There are approximately 820,000 births per annum in France.

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson / Antonia Pollock
Vigo Communications
Sackville House
40 Piccadilly
London W1J 0DR
yourgene@vigocomms.com
T : +44 (0) 20 7390 0230

Two business people looking at computer screen